Researchers found data that showed in patients with rheumatoid arthritis, the delta-tetrahydrocannabinol found in medical cannabis is likely to contribute to an increase in heart rate in patients who are susceptible to atherosclerosis and cardiovascular disease. Medical cannabis was also not found to provide therapeutic effects when comparing it with a combination of cannabinoid type 1 antagonist, fatty acid amide hydrolase inhibitor, and nonpsychotropic cannabidiol.
Researchers found data that support many reasons for infertility in both men and women with rheumatoid arthritis. For the best chance for a successful pregnancy outcome, it is suggested that being on well controlled safe, anti-rheumatic drugs for at least 3 to 6 months prior to pregnancy provides the best chance for women patients with rheumatoid arthritis.
Investigators found data to support the need to tailor individual treatment strategies to improve outcomes in rheumatoid arthritis, which includes further studies to identify biomarkers and patient education about testing and expectations for treatment.
To shed light on this re-emerging phenomenon of physician house calls, MPR interviewed three experts.
Rheumatologists are expected to play an increasing role in the diagnosis and management of patients with cancer with immune checkpoint inhibitor-related rheumatic diseases.
When politicians attempt to make changes to health policy based on sentiments rather than on evidence-based conclusions, physicians often find themselves trying to meet unrealistic expectations.
Researchers found data that showed automated intelligence-based techniques are beneficial in detecting cardiovascular disease caused by the genetic makeup of patients with rheumatoid arthritis.
Rheumatology Advisor interviewed Dr Sofat, who suggests that better control of periodontal disease might improve outcomes in rheumatoid arthritis.
A greater understanding of the mechanisms that promote hypertension in rheumatic diseases will provide insight into understanding primary hypertension.
Understanding genetic factors associated with psoriatic arthritis pathogenesis will support targeted development of new therapies.